VERO Biotech (PRIVATE.VEROBIO)

Overall impact
C (55)

Commentary

VERO Biotech is an average overall performer. With a 'C' rating of 55.1 for overall impact (53rd percentile compared to all companies), VERO Biotech ranks 585th out of 673 industry peers, behind Allena Pharmaceuticals, Pluristem Therapeutics, Cell Source and 581 others, and ahead of Aldeyra Therapeutics, Aptose Biosciences, Apellis Pharmaceuticals and 85 others. On top material causes for VERO Biotech's industry (Biotechnology), VERO Biotech performs well in Child and Maternal Health (95.3 score), Child and Maternal Health (95.3), Improved Mental Health (92.8) and 11 other causes where it received an 'A' score and performs poorly in Reduced Green House Gas Emissions (9.8 score), Decent, Safe Work Opportunities (30.5), Reduced Waste (4.4) and 10 other causes where it received a 'D' or 'F' score.
Impact
Cause PRIVATE.VEROBIO
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
223
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
#<Country/State:0x0000ffff7bcf5af0>, United States
Share classes
PRIVATE.VEROBIO
Description
Manufacturer of inhaled nitric oxide delivery systems intended for patients with pulmonary and cardiac conditions. The company designs, develops, and commercializes portable and tankless devices that provide controlled doses of nitric oxide for hospital use, enabling healthcare providers to support respiratory and cardiovascular treatment without relying on bulky gas cylinders.
Material causes
Ethos considers the following causes material for VERO Biotech, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.